Back to Search
Start Over
A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism.
- Source :
-
Pharmacological research [Pharmacol Res] 2023 Apr; Vol. 190, pp. 106740. Date of Electronic Publication: 2023 Mar 21. - Publication Year :
- 2023
-
Abstract
- Cancer stem cells (CSCs) have been blamed as the main culprit of tumor initiation, progression, metastasis, chemoresistance, and recurrence. However, few anti-CSCs agents have achieved clinical success so far. Here we report a novel derivative of lonidamine (LND), namely HYL001, which selectively and potently inhibits CSCs by targeting mitochondria, with 380-fold and 340-fold lower IC <subscript>50</subscript> values against breast cancer stem cells (BCSCs) and hepatocellular carcinoma stem cells (HCSCs), respectively, compared to LND. Mechanistically, we reveal that HYL001 downregulates glutaminase (GLS) expression to block glutamine metabolism, blunt tricarboxylic acid cycle, and amplify mitochondrial oxidative stress, leading to apoptotic cell death. Therefore, HYL001 displays significant antitumor activity in vivo, both as a single agent and combined with paclitaxel. Furthermore, HYL001 represses CSCs of fresh tumor tissues derived from liver cancer patients. This study provides critical implications for CSCs biology and development of potent anti-CSCs drugs.<br />Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: he authors (Z.L., X.Y., and Q.W.) have applied for patents related to this study.<br /> (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1096-1186
- Volume :
- 190
- Database :
- MEDLINE
- Journal :
- Pharmacological research
- Publication Type :
- Academic Journal
- Accession number :
- 36958408
- Full Text :
- https://doi.org/10.1016/j.phrs.2023.106740